Catalyst Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company was acquired and is no longer a public stock, ending shareholder ownership rights.
Leadership changes after an acquisition signal the company's independence has ended.
Early drug trial results can indicate whether medicines are safe and effective enough to develop further.
Shareholders voted yes on being bought for a set price per share, making the deal official.
Quarterly results show if the company is making money and growing before the merger closes.
Quarterly reports show detailed money and assets, letting investors track company health.
An acquisition deal lets investors sell their shares at an agreed price instead of owning stock.
Stocky reads Catalyst Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Catalyst Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 16 Jul 2026: Merger closes; stock delisted from Nasdaq July 16.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.